Study into early Alzheimer's disease treatments
DPUK enabled experimental medicine Impact Trials
The New Therapeutics into Alzheimer's Disease (NTAD) study is looking to detect markers of the disease before symptoms show. These markers for the disease will be used to test whether experimental treatments can delay, or even prevent, the progression of the disease.
Stem cell resource
Imaging Stem cells
Scientists are studying neurodegenerative disease using stem cells derived from the blood samples of cohort study participants. These cells - iPSCs - are a valuable resource.
Repurposing drug libraries
Impact Stem cells
Scientists are repurposing the drug libraries of AstraZeneca (AZ) on patient-specific cell models. Can they be used for diseases like Alzheimer's and Parkinson's diseases?
Superagers and what they can tell us about dementia
Bringing together cognitive, lifestyle, genetic, biomedical, demographic and psychosocial data will allow researchers to identify the key factors that allow people to live well – without developing dementia.
Tests to bring out the best of existing health studies
cognition
By collaborating with industry partners, DPUK cohorts can access cognitive test technologies to enhance their studies. Computer-adaptive techniques and cloud-based platforms brings industry technology within reach.
Transforming clinical trials with data
Participants in DPUK's cohorts, will be offered the chance to join DPUK's Great Minds register.
Healthy heart, healthy brain?
Many studies indicate that there may be links between heart health and brain health, and this connection may be a promising new avenue in research and development for treatments for brain diseases. DPUK-funded researchers on the Crosstalk study are using large imaging datasets to look for early indicators of brain changes that show up in other organs too.
Can our environment support our brain health?
A DPUK ECR grant winner's research into the links between our environment and brain health has been used to inform a forthcoming World Health Organisation (WHO) report on healthy ageing.
A new lab to investigate the chemical signatures of dementia
A DPUK ECR grant winner is setting up a new lab in Australia to investigate the chemical signatures of healthy ageing and dementia.
Enhancing cognitive assessments
Better methods cognition
This team is developing the cognitive tests that are instrumental in diagnoses of dementia. Sensitive and accurate tests will enable scientists to diagnose dementia earlier – a key focus in the development of new treatments.
DPUK and experimental medicine
DPUK aims to deliver breakthroughs in dementia research through experimental medicine studies. We both directly fund and enable these studies through our technology infrastructure. In many cases, they will recruit through our clinical studies register.
Scanning for amyloid
Amyloid is a brain protein which is associated with dementia, but it is difficult and expensive to detect. This team is conducting brain scans on 500 men and women who are already members of a long-term health study. Their extremely valuable data will be used to develop new, more convenient ways of testing for amyloid in the brain.
Ethical, legal and social issues in DPUK
Better methods Impact
As dementia research is evolving, and as so much of our work is a first for the sector, this team's work looks at the ethical issues arising from DPUK.
Studying the disease that runs in families
Some of the diseases that cause dementia have a genetic element. Looking at familial disease dementia is important because those genetically predisposed to dementia can be analysed for indicators that can then be used to improve our understanding of the other forms of the disease.
Studying the genetics associated with dementia
This team is developing state-of-the-art methods of predicting dementia risk by looking at the genetic data collected by long-term studies of health.
Brain scanning at a new scale
Scanning 10,000 participants a few years after a baseline scan allows for very informative findings about how our brains change as they get older.
Assessing the value of medical records in dementia research
Better methods
This team is working with the data collected by GPs and hospitals, looking to determine how this can help in scientists' understanding of brain diseases such as dementia.
Making best use of donated brains in dementia research
This team has delved into all the issues surrounding brain donation – a crucial element of many studies into dementia.
Profiling the data in existing health studies
This early area of work identified which long-term studies of health – known as 'cohorts' – would be particularly helpful for dementia research, and summarised their information for researchers’ use on the Data Portal.
Looking for the biological signs of Alzheimer's disease
Uncovering the biological signs of change that are associated with the development of Alzheimer's disease is a crucial part of detecting it at its earliest stages and developing effective treatments.